Adaptive Biotechnologies Corporation (ADPT) and ERYTECH Pharma S.A. (NASDAQ:ERYP) Comparison side by side

This is a contrast between Adaptive Biotechnologies Corporation (NASDAQ:ADPT) and ERYTECH Pharma S.A. (NASDAQ:ERYP) based on their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adaptive Biotechnologies Corporation 43 0.00 61.09M -0.44 0.00
ERYTECH Pharma S.A. 5 0.00 10.23M -2.79 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Adaptive Biotechnologies Corporation and ERYTECH Pharma S.A.


Table 2 provides Adaptive Biotechnologies Corporation and ERYTECH Pharma S.A.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Adaptive Biotechnologies Corporation 141,379,310.34% 0% 0%
ERYTECH Pharma S.A. 193,775,689.96% 0% 0%

Analyst Ratings

Recommendations and Ratings for Adaptive Biotechnologies Corporation and ERYTECH Pharma S.A. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Adaptive Biotechnologies Corporation 0 0 0 0.00
ERYTECH Pharma S.A. 0 0 1 3.00

Competitively ERYTECH Pharma S.A. has an average target price of $13, with potential upside of 207.33%.

Insider & Institutional Ownership

Adaptive Biotechnologies Corporation and ERYTECH Pharma S.A. has shares held by institutional investors as follows: 46.2% and 7.77%. Insiders held 4.7% of Adaptive Biotechnologies Corporation shares. Competitively, ERYTECH Pharma S.A. has 0.39% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Adaptive Biotechnologies Corporation -4.53% -3.87% 0% 0% 0% -4.34%
ERYTECH Pharma S.A. -3.97% -15.48% -35.52% -27.74% -71.46% -14.23%

For the past year Adaptive Biotechnologies Corporation was less bearish than ERYTECH Pharma S.A.


Adaptive Biotechnologies Corporation beats on 5 of the 8 factors ERYTECH Pharma S.A.

ERYTECH Pharma Société Anonyme, a clinical-stage biopharmaceutical company, develops therapies for rare forms of cancer and orphan diseases in France and internationally. The company is developing a pipeline of product candidates targeting markets with unmet medical need using its proprietary ERYCAPS platform, a technology to encapsulate therapeutic drug substances inside red blood cells. It primarily focuses on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. The company’s lead product candidate is Eryaspase, which is in various stages of clinical trails for the treatment of pancreatic cancer, ALL, AML, and solid tumors. It is also developing Erymethionase and Eryminase for the treatment of solid tumors; Eryzyme for the treatment of for rare and specialized conditions; and Erymmune for the treatment of TBD. ERYTECH Pharma Société Anonyme has a research agreement with Fox Chase Cancer Center for the preclinical development of erymethionase for the treatment of homocystinuria; a subcontracting agreement for the production of batches of eryaspase for the company's clinical trials; and a subcontracting framework agreement for the optimization of the manufacturing process of the company’s pharma products. ERYTECH Pharma Société Anonyme was founded in 2004 and is based in Lyon, France.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.